 If you're doing all of the above, great, but if not, please tell me which ones aren't in current use. I have attached the creatine information. Surely you are supplying patients already? J Neurol Sci. 0000 Oct 00;000(0-0):000-0. The use of alternative medicine by patients with amyotrophic lateral sclerosis. Wasner M, Klier H, Borasio GD. Department of Neurology and Interdisciplinary Palliative Care Unit, Ludwig Maximilians University, University Hospital, Grosshadern, D-00000, Munich, Germany. The use of complementary and alternative medicine (CAM) is increasing in all industrialised countries, especially in patients with chronic and incurable diseases. However, no data are available on the use of CAM by patients with amyotrophic lateral sclerosis (ALS). The German Association for Neuromuscular Diseases (DGM) mailed out a questionnaire on CAM to 000 ALS patients, 000 of whom completed and returned the survey (response rate 00%). The use of CAM was reported by 00 patients (00%). There were no significant demographic differences between users and nonusers. The patients used 00 different methods or substances; some tried up to 00 different treatments. The most widely used methods were: acupuncture (00%), homeopathy (00%), naturopathy (00%) and esoteric treatments (00%). The lower the patients' expectations from CAM, the better was the subjectively perceived effect. In most cases (00%), alternative treatments were performed by a physician. Patients spent on average 0000 (approximately US$0000) on CAM, generally without reimbursement. CAM is most often used in addition to conventional treatments and may be part of the patients' coping strategy. Open communication between patients and physicians is essential to warn the patients of medically or financially hazardous treatments. Future research should look at the possible palliative effects of CAM on symptom control and quality of life of patients and families. PMID: 00000000 J Herb Pharmacother. 0000;0(0):00-00. The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS). Vardeny O, Bromberg MB. University of Winconsin-Madison School of Pharmacy, Madison, WI, USA. OBJECTIVES: Alternative medicine is widely used in all industrialized Western countries. However, there are no published data regarding the use of botanical or herbal supplements in Ayotrophic Lateral Sclerosis (ALS). Our goal was to survey patients with ALS in our clinic regarding their use of herbal supplements, vitamins, and other therapies or compounds. METHODS: Study subjects participated in the University of Utah Motor Neuron Disease Clinic. An anonymous questionnaire was mailed and designed to assess the following: disease duration and onset site, use of riluzole, alternative therapies (i.e., homeopathy, acupuncture), vitamins, herbal supplements, and other compounds, sources of information about herbal supplements or vitamins, estimated monthly expenditure on vitamins, herbal supplements, and other compounds, and expectations from herbal supplements/vitamins. RESULTS: Fifty-three subjects participated; mean age 00 years old (range 00-00 years), 00 females, 00 males. Symptom duration averaged 0-0 years (00 limb onset, 0 bulbar onset). Thirty-two percent took riluzole and 00% used herbal supplements, 00% took vitamins, and 00% used other compounds (prescription medications used for ALS, but not indicated for ALS). Fifteen percent used alternative therapies. Information about herbal medicines was obtained mostly via friends and relatives (n = 00), a physician (n = 00), and the Internet (n = 0). Our patients selected improvement of general well being and slowing of disease progression most often as reasons for using these therapies. CONCLUSIONS: Our study demonstrated that almost half of patients surveyed utilized herbals supplements, and two thirds of ALS study subjects took vitamins. Twenty-one percent used unproven prescription drugs, and 00% used other alternative therapies. PMID: 00000000 Amyotroph Lateral Scler Other Motor Neuron Disord. 0000 Mar;0(0):0-00. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Desnuelle C, Dib M, Garrel C, Favier A. Service Médecine Physique et de Réadaptation, Maladies Neuromusculaires, CHU de Nice Hĵpital, France. desnuelle.c@chu-nice.fr INTRODUCTION: Increasing evidence suggests that oxidative stress may be involved in the pathogenesis of amyotrophic lateral sclerosis (ALS). The antioxidant vitamin E (alpha-tocopherol) has been shown to slow down the onset and progression of paralysis in transgenic mice expressing a mutation in superoxide dismutase found in certain forms of familial ALS. The current study was designed to determine whether alpha-tocopherol (000 mg b.i.d.) may be efficacious in the treatment of ALS. METHODS: Two hundred and eighty-nine patients with ALS of less than 0 years duration, treated with riluzole, were enrolled in this study, and were randomly assigned to receive either alpha-tocopherol or placebo daily for one year. The primary outcome measure was the rate of deterioration of function assessed by the modified Norris limb scale. Patients were assessed at entry, and every 0 months thereafter during the study period. Survival was also recorded. Biochemical markers of oxidative stress were measured in a subset of patients on entry and after 0 months of treatment. RESULTS: After 00 months of treatment, alpha-tocopherol had no effect on the primary outcome measure. Survival was not influenced by treatment. Among secondary outcome measures, patients given alpha-tocopherol were less likely to progress from the milder state A to the more severe state B (P=0.000) of the ALS Health State scale. After 0 months treatment, analysis of oxidative stress markers showed an increase in glutathione peroxidase activity in plasma (P = 0.0000) and a decrease in plasma levels of thiobarbituric acid reactive species (P = 0.0000) in the group of patients given alpha-tocopherol in combination with riluzole. CONCLUSION: Although alpha-tocopherol did not appear to affect the survival and motor function in ALS, patients receiving riluzole plus alpha-tocopherol remained longer in the milder states of the ALS Health State scale and showed, after 0 months, changes in biochemical markers of oxidative stress. Further studies are required to confirm the greater sensitivity of the ALS Health State scale over other clinical endpoints. PMID: 00000000 J Neural Transm. 0000 May;000(0):000-00. Epub 0000 Oct 00. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, Hager C, Ludolph AC, Becker G, Osterhage J, Jost WH, Schrank B, Stein C, Kostopulos P, Lubik S, Wekwerth K, Dengler R, Troeger M, Wuerz A, Hoge A, Schrader C, Schimke N, Krampfl K, Petri S, Zierz S, Eger K, Neudecker S, Traufeller K, Sievert M, Neundörfer B, Hecht M; German vitamin E/ALS Study Group.